NASDAQ:FBRX Forte Biosciences (FBRX) Stock Price, News & Analysis → Central Banks Preparing for US Dollar Collapse? (From Behind the Markets) (Ad) Free FBRX Stock Alerts $0.70 0.00 (0.00%) (As of 03/28/2024 ET) Add Compare Share Share Today's Range$0.67▼$0.7450-Day Range$0.49▼$0.7652-Week Range$0.38▼$1.29Volume52,347 shsAverage Volume27,901 shsMarket Capitalization$25.34 millionP/E RatioN/ADividend YieldN/APrice TargetN/A Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial MediaStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSocial Media Get Forte Biosciences alerts: Email Address Ad Vertical Research Advisory“The Stock Market’s Bull Run is Far from Over” -BarronsBarron's reports that the "stock market's bull run is FAR from over…" And recent economic growth will fuel the price of select stocks in the coming months!Click here for all the details now… About Forte Biosciences Stock (NASDAQ:FBRX)Forte Biosciences, Inc. operates as a biopharmaceutical company in the United States. It is developing FB-102 program that addresses various autoimmune diseases, such as graft-versus-host disease, and vitiligo and alopecia areata. The company is headquartered in Dallas, Texas.Read More FBRX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart FBRX Stock News HeadlinesMarch 25, 2024 | americanbankingnews.comForte Biosciences, Inc. (NASDAQ:FBRX) Forecasted to Earn FY2024 Earnings of ($0.41) Per ShareMarch 21, 2024 | americanbankingnews.comInvestors Purchase Large Volume of Forte Biosciences Call Options (NASDAQ:FBRX)March 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.March 19, 2024 | investorplace.comFBRX Stock Earnings: Forte Biosciences Reported Results for Q4 2023March 18, 2024 | businesswire.comForte Biosciences, Inc. Announces 2023 Results and Provides Business UpdateDecember 12, 2023 | morningstar.comForte Biosciences Inc Ordinary SharesDecember 9, 2023 | finance.yahoo.comWe Think Forte Biosciences (NASDAQ:FBRX) Needs To Drive Business Growth CarefullyNovember 15, 2023 | morningstar.comForte Biosciences Inc Ordinary Shares FBRXMarch 29, 2024 | Behind the Markets (Ad)Central Banks Preparing for US Dollar Collapse?China is spearheading this blatant de-dollarization push, dominating the physical gold market through massive central bank buying. Their ultimate goal? Ditching the greenback in favor of local BRICS currencies.November 14, 2023 | msn.comForte Biosciences GAAP EPS of -$0.26November 13, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Third Quarter 2023 Results and Provides Business UpdateSeptember 14, 2023 | benzinga.comISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company's Upcoming Annual MeetingSeptember 14, 2023 | finance.yahoo.comISS and Glass Lewis Recommend Forte Biosciences Stockholders Vote FOR Boardroom Change at the Company’s Upcoming Annual MeetingSeptember 6, 2023 | finance.yahoo.comConcerned Stockholders of Forte Biosciences and Its Independent Director Candidates Share Key Facts that Reinforce the Need for Urgent Change in the Company’s BoardroomAugust 25, 2023 | businesswire.comConcerned Stockholders of Forte Biosciences File Definitive Proxy Statement and Send Letter to StockholdersAugust 25, 2023 | 247wallst.comCamac Fund Now Owns 4.3% of Forte BiosciencesAugust 14, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Second Quarter 2023 Results and Provides Business UpdateAugust 3, 2023 | benzinga.comChief Financial Officer At This Health Care Company Buys $149K of StockAugust 1, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces $25 Million Financing and R&D Update for FB-102July 4, 2023 | finance.yahoo.comThis Forte Biosciences Insider Increased Their Holding In The Last YearMay 24, 2023 | finance.yahoo.comWe're Not Very Worried About Forte Biosciences' (NASDAQ:FBRX) Cash Burn RateMay 19, 2023 | finance.yahoo.comForte Biosciences, Inc. Reports Inducement Grant Under Nasdaq Listing RulesMay 15, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces First Quarter 2023 Results and Provides Business UpdateApril 6, 2023 | msn.comUnusual Call Option Trade in Forte Biosciences (FBRX) Worth $2.50KMarch 31, 2023 | finance.yahoo.comForte Biosciences, Inc. Announces Full Year 2022 Results and Provides Business UpdateJanuary 28, 2023 | seekingalpha.comFBRX Forte Biosciences, Inc.January 25, 2023 | finance.yahoo.comOne Forte Biosciences, Inc. (NASDAQ:FBRX) insider upped their stake by 7.8% in the previous yearSee More Headlines Receive FBRX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Forte Biosciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings11/18/2021Today3/28/2024Next Earnings (Estimated)5/20/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:FBRX CUSIPN/A CIK1419041 Webwww.fortebiorx.com Phone(310) 618-6994FaxN/AEmployees9Year FoundedN/AProfitability EPS (Most Recent Fiscal Year)($1.04) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-31,480,000.00 Net MarginsN/A Pretax MarginN/A Return on Equity-94.27% Return on Assets-81.36% Debt Debt-to-Equity RatioN/A Current Ratio10.45 Quick Ratio10.45 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.97 per share Price / Book0.72Miscellaneous Outstanding Shares36,400,000Free Float32,563,000Market Cap$25.34 million OptionableOptionable Beta0.48 The Next 7 Blockbuster Stocks for Growth InvestorsWondering what the next stocks will be that hit it big, with solid fundamentals? Click the link below to learn more about how your portfolio could bloom.Get This Free Report Key ExecutivesDr. Paul A. Wagner Ph.D. (Age 54)CEO, President & Chairman Comp: $914.5kMr. Christopher RoenfeldtChief Operating OfficerMr. Steven Ruhl (Age 67)Chief Technical Officer Key CompetitorsMEI PharmaNASDAQ:MEIPCumberland PharmaceuticalsNASDAQ:CPIXSensei BiotherapeuticsNASDAQ:SNSELisata TherapeuticsNASDAQ:LSTACalciMedicaNASDAQ:CALCView All CompetitorsInsiders & InstitutionsCable Car Capital LLCBought 2,031,987 shares on 2/20/2024Ownership: 5.593%Citadel Advisors LLCBought 100 shares on 2/15/2024Ownership: 0.000%Paul A WagnerBought 10,000 shares on 12/18/2023Total: $7,500.00 ($0.75/share)Paul A WagnerBought 10,520 shares on 12/13/2023Total: $7,364.00 ($0.70/share)Paul A WagnerBought 25,000 shares on 12/11/2023Total: $16,250.00 ($0.65/share)View All Insider TransactionsView All Institutional Transactions FBRX Stock Analysis - Frequently Asked Questions Should I buy or sell Forte Biosciences stock right now? 1 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Forte Biosciences in the last year. There are currently 1 hold rating for the stock. The consensus among Wall Street research analysts is that investors should "hold" FBRX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in FBRX, but not buy additional shares or sell existing shares. View FBRX analyst ratings or view top-rated stocks. How have FBRX shares performed in 2024? Forte Biosciences' stock was trading at $0.8217 at the beginning of the year. Since then, FBRX stock has decreased by 15.3% and is now trading at $0.6962. View the best growth stocks for 2024 here. When is Forte Biosciences' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Monday, May 20th 2024. View our FBRX earnings forecast. How were Forte Biosciences' earnings last quarter? Forte Biosciences, Inc. (NASDAQ:FBRX) issued its earnings results on Monday, March, 18th. The company reported ($0.04) EPS for the quarter. What other stocks do shareholders of Forte Biosciences own? Based on aggregate information from My MarketBeat watchlists, some companies that other Forte Biosciences investors own include Trevena (TRVN), Chimerix (CMRX), electroCore (ECOR), Great Panther Mining (GPL), Immunic (IMUX), Infinera (INFN) and Stride (LRN). Who are Forte Biosciences' major shareholders? Forte Biosciences' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Cable Car Capital LLC (5.59%), Citadel Advisors LLC (0.00%) and Concourse Financial Group Securities Inc. (0.00%). Insiders that own company stock include Paul A Wagner and Paul A Wagner. View institutional ownership trends. How do I buy shares of Forte Biosciences? Shares of FBRX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:FBRX) was last updated on 3/29/2024 by MarketBeat.com Staff From Our PartnersTrump’s “Tax Free” Retirement Strategy Gold Safe ExchangeDid You Get Your Free Bitcoin Yet?Crypto Swap ProfitsTop Project Outperforms BTC in 2023…Crypto 101 MediaMake This $3 Trade the Instant the Opening Bell RingsMonument Traders Alliance“The Stock Market’s Bull Run is Far from Over” -BarronsVertical Research AdvisoryAI Cracks Open Largest Untapped Energy Reserve on EarthBanyan Hill PublishingThis AI Trade Machine Made 1,729%* (With 89% Wins)Prosper Trading AcademyOnly a fool would buy Nvidia today… Porter & Company Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Forte Biosciences, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Get 30 Days of MarketBeat All Access Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools: Best-in-Class Portfolio Monitoring View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio. Stock Ideas and Recommendations Get daily stock ideas from top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report. Advanced Stock Screeners and Research Tools Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis. Start Your 30-Day Free Trial Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Your Password: or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Choose a Password: Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.